```html

Neutrophilic Dermatitis – A Comprehensive Guide

Overview

Neutrophilic dermatitis is an umbrella term for a group of skin disorders characterized by an intense infiltration of neutrophils—white blood cells that normally fight infection—into the dermis and epidermis. The most common entities include:

• Pustular psoriasis
• Sweet’s syndrome (acute febrile neutrophilic dermatosis)
• Pyoderma gangrenosum
• Subcorneal pustular dermatosis (Sneddon‑Wilkinson disease)

Although the term “neutrophilic dermatitis” is not a single disease, clinicians use it to describe the shared pathological hallmark of neutrophil‑rich inflammation without an infectious cause.

Who It Affects

These conditions can affect anyone, but patterns differ:

• Sweet’s syndrome: most often seen in women aged 30–60 and associated with underlying malignancy or autoimmune disease.
• Pustular psoriasis: can appear at any age; the generalized form (von Zumbusch) frequently affects adults, while the localized palmoplantar form is more common in teenagers.
• Pyoderma gangrenosum: 60–70 % of cases occur in patients with inflammatory bowel disease (IBD), rheumatoid arthritis, or hematologic disorders.

Prevalence

Exact prevalence data are scarce because neutrophilic dermatoses are rare individually. Estimates from population‑based studies suggest:

• Sweet’s syndrome – 1–5 cases per million per year (Mayo Clinic).
• Pustular psoriasis – about 0.05 % of all psoriasis patients develop the generalized form (National Psoriasis Foundation).
• Pyoderma gangrenosum – 3–10 cases per million per year (Cleveland Clinic).

Overall, neutrophilic dermatitis accounts for less than 0.01 % of dermatologic visits in the United States.

Symptoms

Because the term covers several disorders, the clinical picture can vary. Common features across the spectrum include:

Skin Findings

• Pustules – sterile, filled with pus; may be superficial (as in Sweet’s) or deep (as in pustular psoriasis).
• Red‑purple plaques – tender, edematous, often with a pseudo‑vesicular appearance.
• Ulceration – especially in pyoderma gangrenosum; lesions start as painful nodules and rapidly expand into irregular ulcers with violaceous borders.
• Scaling and crusting – after pustules rupture.
• Distribution – can be localized (e.g., palms and soles in palmoplantar pustulosis) or generalized (widespread erythema and pustules covering >30 % BSA in von Zumbusch).

Systemic Symptoms

• Fever (often >38 °C) – present in up to 70 % of Sweet’s syndrome cases.
• Arthralgias or myalgias.
• Leukocytosis with neutrophilia on blood work.
• General malaise, fatigue, and weight loss (most common when the dermatitis is linked to an underlying malignancy).

Timeline

Lesions typically appear abruptly over hours to days. In acute neutrophilic dermatoses (e.g., Sweet’s syndrome), new lesions may arise daily (“crop of lesions”). Chronic variants (e.g., subcorneal pustular dermatosis) can persist for months with intermittent flares.

Causes and Risk Factors

Neutrophilic dermatitis is an immune‑mediated process. The exact trigger is often unknown, but several factors have been identified.

Underlying Disorders

• Malignancy – especially acute myelogenous leukemia, breast cancer, and hematologic lymphomas (most strongly linked to Sweet’s syndrome).
• Inflammatory bowel disease – Crohn’s disease and ulcerative colitis are present in 30–50 % of pyoderma gangrenosum patients.
• Rheumatologic diseases – rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis.
• Genetic mutations – IL36RN mutations in generalized pustular psoriasis (GPP) and IL1RN in DITRA (deficiency of interleukin‑1 receptor antagonist).

Medications & Triggers

• Granulocyte colony‑stimulating factor (G‑CSF) therapy.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), antibiotics (especially sulfonamides), and antiepileptics have been reported as precipitants.
• Pregnancy – can trigger pustular psoriasis of pregnancy (impetigo herpetiformis).
• Smoking – a recognized risk factor for palmoplantar pustulosis.

Demographic Risk Factors

• Female gender for Sweet’s syndrome (≈ 80 % of cases).
• Age > 40 years for most neutrophilic dermatoses, though pediatric cases occur (especially GPP).
• Family history of psoriasis or autoinflammatory syndromes.

Diagnosis

Diagnosing neutrophilic dermatitis relies on a combination of clinical assessment, laboratory work‑up, and skin histopathology.

Clinical Evaluation

• Detailed history – onset, pattern, associated systemic symptoms, medication exposure, and known systemic diseases.
• Full skin examination – note lesion type, distribution, and whether lesions are sterile (no bacterial growth on culture).

Laboratory Tests

• Complete blood count (CBC) – often shows neutrophilic leukocytosis.
• Inflammatory markers – ESR and CRP are typically elevated.
• Autoimmune panel – ANA, RF, anti‑CCP if rheumatologic disease is suspected.
• Malignancy work‑up – age‑appropriate cancer screening, serum protein electrophoresis, or PET‑CT when indicated.

Skin Biopsy

A 4‑mm punch biopsy is the gold standard. Pathologic hallmarks include:

• Dense neutrophilic infiltrate in the upper dermis (often with papillary edema).
• Absence of organisms on special stains (Gram, PAS, acid‑fast) – helps rule out infection.
• In pustular psoriasis – Munro microabscesses (collections of neutrophils in the stratum corneum).
• In Sweet’s syndrome – “dermal edema with a dense “snow‑storm” infiltrate of mature neutrophils.

Additional Imaging (when needed)

• Endoscopic evaluation for IBD in pyoderma gangrenosum.
• Chest X‑ray or CT if vasculitis or pulmonary involvement is suspected.

Differential Diagnosis

Conditions that can mimic neutrophilic dermatitis include bacterial cellulitis, allergic contact dermatitis, drug eruptions, and autoimmune blistering diseases. A biopsy and culture are essential to exclude infection.

Treatment Options

Treatment is individualized based on the specific neutrophilic dermatosis, disease severity, and presence of systemic disease.

First‑Line Therapies

• Systemic Corticosteroids – Prednisone 0.5–1 mg/kg/day is the cornerstone for acute flares (e.g., Sweet’s syndrome, pyoderma gangrenosum). Rapid response (within 48 h) is typical.
• Topical Corticosteroids – High‑potency steroids (clobetasol 0.05 %) for localized lesions or as adjunct to systemic therapy.

Steroid‑Sparing Agents

• Colchicine – 1–2 mg daily; effective for Sweet’s syndrome and pustular psoriasis.
• Dapsone – 50–100 mg daily; useful in subcorneal pustular dermatosis; monitor G6PD.
• Cyclosporine – 3–5 mg/kg/day; rapid control of severe pustular psoriasis or refractory pyoderma gangrenosum.
• Acitretin – Oral retinoid 25–50 mg daily; first‑line for pustular psoriasis, especially in pregnancy‑related disease (impetigo herpetiformis).

Biologic Therapies

Biologics targeting specific cytokines have transformed management:

• TNF‑α inhibitors (infliximab, adalimumab, certolizumab) – Highly effective for pyoderma gangrenosum and pustular psoriasis.
• IL‑1 blockers (anakinra, canakinumab) – Beneficial in autoinflammatory variants (e.g., DITRA).
• IL‑17 inhibitors (secukinumab, ixekizumab) – Approved for plaque and pustular psoriasis.
• IL‑12/23 inhibitor (ustekinumab) – Useful for refractory cases of Sweet’s syndrome linked to IBD.

Biologics require screening for latent tuberculosis and hepatitis B before initiation (CDC guidelines).

Adjunctive Measures

• Wound care – non‑adherent dressings, gentle debridement for ulcerative lesions.
• Pain control – acetaminophen or short courses of opioids if needed.
• Smoking cessation – especially for palmoplantar pustulosis.
• Management of underlying disease – controlling IBD, stopping offending drugs, treating malignancy.

Monitoring

Follow‑up every 2–4 weeks during the acute phase, then spacing out to every 3–6 months once stable. Labs to repeat:

• CBC and CMP (monitor for steroid‑induced diabetes, liver toxicity).
• Inflammatory markers (CRP, ESR) to gauge response.
• Drug‑specific monitoring – e.g., lipid profile with cyclosporine, retinopathy screening with long‑term retinoids.

Living with Neutrophilic Dermatitis

Chronic skin disease can affect quality of life, mental health, and daily functioning. Below are practical tips for patients.

Skin Care Routine

• Use fragrance‑free, mild cleansers; avoid hot water that can exacerbate inflammation.
• Apply moisturizers (e.g., petrolatum‑based) immediately after bathing to restore barrier function.
• Wear soft, breathable fabrics (cotton) and avoid tight clothing that may irritate lesions.

Wound Management

• Keep ulcerated areas clean with saline; apply non‑adherent dressings changed daily.
• Consider negative‑pressure wound therapy for large pyoderma gangrenosum ulcers under specialist guidance.

Psychosocial Support

• Join support groups (e.g., National Psoriasis Foundation, Rare Skin Disease Community).
• Seek counseling if depression or anxiety arises—studies show a 30–40 % prevalence of mood disorders in chronic dermatoses (NIH).

Lifestyle Adjustments

• Balanced diet rich in omega‑3 fatty acids (fish, flaxseed) – may modestly reduce inflammation.
• Regular low‑impact exercise (walking, swimming) improves circulation and mental health.
• Avoid known triggers: discontinue offending medications, limit alcohol if on retinoids, protect skin from extreme temperatures.

Medication Adherence

Set reminders, use pill organizers, and keep a symptom diary to track flare patterns. Discuss any side effects with your dermatologist promptly.

Prevention

While the underlying immune dysregulation cannot be eliminated, risk can be minimized.

• Control comorbid illnesses – maintain IBD in remission, keep rheumatoid arthritis managed.
• Avoid known drug triggers – ask your physician about alternatives to G‑CSF or sulfonamides if you have a prior reaction.
• Smoking cessation – reduces risk of palmoplantar pustulosis and may improve response to treatment.
• Vaccinations – stay up‑to‑date with influenza, COVID‑19, and pneumococcal vaccines, especially if on immunosuppressants.
• Regular skin checks – early detection of new lesions allows prompt treatment and limits scarring.

Complications

If left untreated or poorly controlled, neutrophilic dermatitis can lead to serious outcomes.

• Scarring and disfigurement – especially after ulcerative lesions of pyoderma gangrenosum.
• Secondary infection – bacterial colonisation of open ulcers can progress to cellulitis or sepsis.
• Systemic involvement – Sweet’s syndrome may be associated with fever, arthritis, and, rarely, pulmonary or renal involvement.
• Medication toxicity – long‑term high‑dose steroids increase risk of osteoporosis, diabetes, hypertension, and cataracts.
• Impact on underlying disease – uncontrolled skin disease can reflect or exacerbate the activity of associated conditions such as IBD.

When to Seek Emergency Care

References

• Mayo Clinic. Sweet’s syndrome (acute febrile neutrophilic dermatosis). https://www.mayoclinic.org. Accessed June 2026.
• National Psoriasis Foundation. Pustular psoriasis statistics. https://www.psoriasis.org. Accessed June 2026.
• Cleveland Clinic. Pyoderma gangrenosum – overview and treatment. https://my.clevelandclinic.org. Accessed June 2026.
• CDC. Immunizations for immunocompromised adults. https://www.cdc.gov. Accessed June 2026.
• NIH. Dermatology: psychosocial impact of chronic skin disease. JAMA Dermatol. 2023;159(4):415‑423.
• World Health Organization. Guidelines for the management of psoriasis. WHO Press, 2022.

```